Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in patients with heart failure (HF), but the evidence of their efficacy in patients who have had an acute myocardial infarction (AMI) is still incompletely established. The gene discussed is SLC5A2; the disease is hydrops fetalis.